

National Phase Entry of
International Application No.:
PCT/GB97/02108 which was filed:
August 5, 1997

Please amend the application as follows, and consider the remarks set forth thereafter.

In the specification:

On page 5, line 27, replace --Texas Red-- with ~~--TEXAS RED®--~~.

After page 58, add a new page 59. On new page 59, add the following paragraph:

~~--ABSTRACT~~

B¹
A method of determining premalignant or neoplastic disease state in a tissue sample containing cells of the cervix, the method comprising contacting specific monoclonal antibodies to a cervical tissue sample, determining binding of the antibodies to the sample and comparing the binding with a pattern of binding of the same antibodies to a normal cervical cell sample. Hybridomas which produce suitable antibodies have been deposited at the European Collection of Animal Cell Cultures (ECACC) under the accession numbers ECACC 95020718, 95020716, 95020720, 95020717 and 95020719.

In the claims:

On page 56, line 1, replace "CLAIMS:" with ~~--WE CLAIM:--~~

Please delete claims ~~6 and 9~~, without prejudice or disclaimer.

Please amend the claims as follows:

Sub C1
B²
1. (AMENDED) A method of determining [abnormality] a premalignant or neoplastic disease state in a tissue sample containing cells of the cervix, the method comprising contacting a panel of two or more monoclonal antibodies with said tissue sample, determining binding of [specific binding substances] said monoclonal antibodies to [the] said sample and comparing the binding with [the] a pattern of binding of said [specific binding substances] monoclonal antibodies to a normal cervical cell sample, wherein said monoclonal antibodies detect cellular markers which differ between normal and premalignant or neoplastic cells.